158 related articles for article (PubMed ID: 36576236)
21. Oncogenic
Boutin AT; Liao WT; Wang M; Hwang SS; Karpinets TV; Cheung H; Chu GC; Jiang S; Hu J; Chang K; Vilar E; Song X; Zhang J; Kopetz S; Futreal A; Wang YA; Kwong LN; DePinho RA
Genes Dev; 2017 Feb; 31(4):370-382. PubMed ID: 28289141
[TBL] [Abstract][Full Text] [Related]
22. TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway.
Trobridge P; Knoblaugh S; Washington MK; Munoz NM; Tsuchiya KD; Rojas A; Song X; Ulrich CM; Sasazuki T; Shirasawa S; Grady WM
Gastroenterology; 2009 May; 136(5):1680-8.e7. PubMed ID: 19208363
[TBL] [Abstract][Full Text] [Related]
23. BRAF
Reischmann N; Andrieux G; Griffin R; Reinheckel T; Boerries M; Brummer T
Oncogene; 2020 Sep; 39(38):6053-6070. PubMed ID: 32792685
[TBL] [Abstract][Full Text] [Related]
24. A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers.
Cheng R; Li F; Zhang M; Xia X; Wu J; Gao X; Zhou H; Zhang Z; Huang N; Yang X; Zhang Y; Shen S; Kang T; Liu Z; Xiao F; Yao H; Xu J; Yan C; Zhang N
Cell Res; 2023 Jan; 33(1):30-45. PubMed ID: 36241718
[TBL] [Abstract][Full Text] [Related]
25. Probing the tumorigenic potential of genetic interactions reconstituted in murine fallopian tube organoids.
Maru Y; Tanaka N; Tatsumi Y; Nakamura Y; Yao R; Noda T; Itami M; Hippo Y
J Pathol; 2021 Oct; 255(2):177-189. PubMed ID: 34184756
[TBL] [Abstract][Full Text] [Related]
26. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
[TBL] [Abstract][Full Text] [Related]
27. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
[TBL] [Abstract][Full Text] [Related]
28. Cancer stemness in Apc- vs. Apc/KRAS-driven intestinal tumorigenesis.
Ghazvini M; Sonneveld P; Kremer A; Franken P; Sacchetti A; Atlasi Y; Roth S; Joosten R; Smits R; Fodde R
PLoS One; 2013; 8(9):e73872. PubMed ID: 24069241
[TBL] [Abstract][Full Text] [Related]
29. Identification of subsets of actionable genetic alterations in KRAS-mutant lung cancers using association rule mining.
Tayou J
Cell Oncol (Dordr); 2018 Aug; 41(4):395-408. PubMed ID: 29679238
[TBL] [Abstract][Full Text] [Related]
30. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
[TBL] [Abstract][Full Text] [Related]
31. Human gastric cancer modelling using organoids.
Seidlitz T; Merker SR; Rothe A; Zakrzewski F; von Neubeck C; Grützmann K; Sommer U; Schweitzer C; Schölch S; Uhlemann H; Gaebler AM; Werner K; Krause M; Baretton GB; Welsch T; Koo BK; Aust DE; Klink B; Weitz J; Stange DE
Gut; 2019 Feb; 68(2):207-217. PubMed ID: 29703791
[TBL] [Abstract][Full Text] [Related]
32. Interaction of the Wnt/β-catenin and RAS-ERK pathways involving co-stabilization of both β-catenin and RAS plays important roles in the colorectal tumorigenesis.
Lee SK; Hwang JH; Choi KY
Adv Biol Regul; 2018 May; 68():46-54. PubMed ID: 29449169
[TBL] [Abstract][Full Text] [Related]
33. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
[TBL] [Abstract][Full Text] [Related]
34. Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties.
Nakayama M; Hong CP; Oshima H; Sakai E; Kim SJ; Oshima M
Nat Commun; 2020 May; 11(1):2333. PubMed ID: 32393735
[TBL] [Abstract][Full Text] [Related]
35. Analysis of Aged Dysfunctional Intestinal Stem Cells.
Nalapareddy K; Geiger H
Methods Mol Biol; 2020; 2171():41-52. PubMed ID: 32705634
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C.
Cannataro VL; Gaffney SG; Stender C; Zhao ZM; Philips M; Greenstein AE; Townsend JP
Oncogene; 2018 May; 37(18):2444-2455. PubMed ID: 29453361
[TBL] [Abstract][Full Text] [Related]
37. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
38. Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?
Baretti M; Personeni N; Destro A; Santoro A; Rimassa L
Cancer Biol Ther; 2018 Aug; 19(8):659-663. PubMed ID: 29580164
[TBL] [Abstract][Full Text] [Related]
39. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer.
Morton JP; Timpson P; Karim SA; Ridgway RA; Athineos D; Doyle B; Jamieson NB; Oien KA; Lowy AM; Brunton VG; Frame MC; Evans TR; Sansom OJ
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):246-51. PubMed ID: 20018721
[TBL] [Abstract][Full Text] [Related]
40. Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2).
Beau-Faller M; Texier M; Blons H; Richard N; Escande F; Melaabi S; Lizard S; De Fraipont F; Longchampt E; Morin F; Zalcman G; Pignon JP; Cadranel J
Clin Lung Cancer; 2019 May; 20(3):222-230. PubMed ID: 30679079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
